A JAK2-V617F activating mutation in addition to KIT and FLT3 mutations is associated with clinical outcome in patients with t(8;21)(q22;q22) acute myeloid leukemia (Q43171541)
Jump to navigation
Jump to search
scientific article published on 30 January 2009
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A JAK2-V617F activating mutation in addition to KIT and FLT3 mutations is associated with clinical outcome in patients with t(8;21)(q22;q22) acute myeloid leukemia |
scientific article published on 30 January 2009 |
Statements
1 reference
A JAK2-V617F activating mutation in addition to KIT and FLT3 mutations is associated with clinical outcome in patients with t(8;21)(q22;q22) acute myeloid leukemia (English)
1 reference
Eisaku Iwanaga
1 reference
Tomoko Nanri
1 reference
Naofumi Matsuno
1 reference
Toshiro Kawakita
1 reference
Hiroaki Mitsuya
1 reference
Norio Asou
1 reference
30 January 2009
1 reference
1 reference
94
1 reference
433-435
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference